Mark Neumann

 
Background and Education
 
Mark Neumann is a seasoned professional in the biopharmaceutical industry with a career that spans over 35 years. His journey began with an AB in Economics and Business Administration from Lafayette College, where he cultivated a strong educational foundation that would inform his future roles.

 
Early Career
 
Mark’s career started at Arthur Andersen & Co. as a staff and senior accountant, where he was recognized with an accelerated promotion due to his impressive work in field audits. In 1988, he moved to Bristol-Myers Squibb, marking the beginning of a long and impactful tenure there. Over the course of nearly three decades, Mark worked in various capacities, ranging from sales and marketing to finance. He steadily climbed the ranks, holding pivotal roles such as Vice President and Global Brand Lead across multiple therapeutic areas including cardiovascular, neuroscience, and virology. Notably, he played a crucial role in the development and commercialization of major pharmaceutical products like Eliquis®, Pravachol, and Plavix.

 
Amgen Tenure
 
In 2013, Mark transitioned to Amgen, where he first served as Vice President and Head of Sales for the U.S. Diabetes Business Unit before moving on to lead the Bone Health, Inflammation, and Nephrology sectors as Vice President of Global Marketing. During his time at Amgen, Mark was instrumental in launching key products such as Repatha® and Corlanor®, significantly contributing to the company's global strategies and commercial success.

 
Current Role at Intra-Cellular Therapies
 
Mark's current and perhaps most transformative role began in October 2018 when he joined Intra-Cellular Therapies as Executive Vice President and Chief Commercial Officer. Here, he successfully guided the company from its clinical-stage beginnings to becoming a fully integrated R&D and commercial organization. One of his notable achievements includes the launch of CAPLYTA® for schizophrenia, followed by an expansion of its label to include bipolar depression. Under his leadership, the company's revenue soared to $462 million in 2023, with projections exceeding $650 million for 2024. He also played a vital role in raising $1.6 billion through four public stock offerings, greatly enhancing shareholder value and market capitalization.

 
Leadership Qualities
 
Throughout his career, Mark has been lauded for his strategic vision and leadership, qualities that have consistently driven organizational growth and enriched stakeholder value. His diverse experience across sales, marketing, and financial management, coupled with his deep understanding of various therapeutic areas, paints a picture of an executive who is both versatile and highly effective in the competitive landscape of the biopharmaceutical industry.